



Supplementary figure S1.

A




B



Supplementary figure S2.


A



B


SK-LU-1 treated with DMSO

AGC G AGG GG AAT T T G AG C G G G A G G G T T T T G A G A G G A G C G G G A G G T T G C G






SK-LU-1 treated with 5-aza-dC

AGC G AGG GG AAT T T G AG C G G G A G G G T T T T G A G A G G A G C G G G A G G T T G C G




Supplementary figure S3.




Supplementary figure S4.

A




B



miR-34b/c methylation	<i>n</i>	Events (%)	Median DFS (95% CI)
Low to medium	93	39 (42%)	Not reached
High (AUC > 1.34)	47	33 (70%)	19.9 (1.4-38.4)

miR-34b/c methylation	<i>n</i>	Events (%)	Median OS (95% CI)
Low to medium	92	37 (40%)	Not reached
High (AUC > 1.34)	46	26 (43%)	15.6 (21.6-82.7)



Supplementary figure S5.




miR-34b/c methylation	<i>n</i>	Events (%)	Median DFS (95% CI)
Low to medium	68	22 (32%)	Not reached
High (AUC > 1.34)	28	16 (57%)	43.1 (4.1-85.7)

Supplementary figure S6.


A



B




C




Supplementary figure S7.

A



B



Supplementary figure S8.

